Compare Stocks: AKBA, CSLLY, GSK, and GSK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.88 -6.5%	$1.14	$0.81 ▼ $3.22	$260.42M	0.26	7.30 million shs	10.17 million shs
CSLLY CSL	$30.92 -1.3%	$23.24	$16.01 ▼ $36.29	$60.04B	0.57	132,845 shs	125,243 shs
GSK GSK	$50.80 +1.1%	$51.82	$38.63 ▼ $61.69	$101.68B	0.36	3.12 million shs	3.43 million shs
GSK GSK	$50.80 +1.1%	$51.82	$38.63 ▼ $61.69	$101.68B	0.36	3.12 million shs	3.43 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-6.51%	-3.09%	-30.27%	-13.86%	-70.81%
CSLLY CSL	-1.34%	+2.18%	+39.34%	+77.60%	-55.86%
GSK GSK	+1.05%	-3.27%	-4.42%	+0.46%	+27.19%
GSK GSK	+1.05%	-3.27%	-4.42%	+0.46%	+27.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.88 -6.5%	$1.14	$0.81 ▼ $3.22	$260.42M	0.26	7.30 million shs	10.17 million shs
CSLLY CSL	$30.92 -1.3%	$23.24	$16.01 ▼ $36.29	$60.04B	0.57	132,845 shs	125,243 shs
GSK GSK	$50.80 +1.1%	$51.82	$38.63 ▼ $61.69	$101.68B	0.36	3.12 million shs	3.43 million shs
GSK GSK	$50.80 +1.1%	$51.82	$38.63 ▼ $61.69	$101.68B	0.36	3.12 million shs	3.43 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-6.51%	-3.09%	-30.27%	-13.86%	-70.81%
CSLLY CSL	-1.34%	+2.18%	+39.34%	+77.60%	-55.86%
GSK GSK	+1.05%	-3.27%	-4.42%	+0.46%	+27.19%
GSK GSK	+1.05%	-3.27%	-4.42%	+0.46%	+27.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.33	Hold	$3.75	326.82% Upside
CSLLY CSL	2.00	Hold	N/A	N/A
GSK GSK	2.10	Hold	$53.00	4.33% Upside
GSK GSK	2.10	Hold	$53.00	4.33% Upside

Current Analyst Ratings Breakdown

Latest AKBA, CSLLY, GSK, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	GSK GSK	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight
8/25/2026	GSK GSK	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/7/2026	CSLLY CSL	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/30/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/30/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/29/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
7/29/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$219.06M	1.11	N/A	N/A	$0.09 per share	9.76
CSLLY CSL	$15.80B	3.75	$2.16 per share	14.33	$11.05 per share	2.80
GSK GSK	$43.07B	2.39	$6.07 per share	8.37	$11.40 per share	4.46
GSK GSK	$43.07B	2.39	$6.07 per share	8.37	$11.40 per share	4.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
CSLLY CSL	-$2.58B	N/A	N/A	18.63	2.92	N/A	N/A	N/A	N/A
GSK GSK	$7.54B	$3.20	15.88	10.06	2.90	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
GSK GSK	$7.54B	$3.20	15.88	10.06	2.90	14.56%	43.23%	11.60%	10/28/2026 (Estimated)

Latest AKBA, CSLLY, GSK, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CSLLY CSL	$0.59	1.91%	N/A	N/A	N/A
GSK GSK	$1.78	3.50%	-7.86%	55.63%	N/A
GSK GSK	$1.78	3.50%	-7.86%	55.63%	N/A

Latest AKBA, CSLLY, GSK, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
CSLLY CSL	0.51	2.57	1.15
GSK GSK	0.81	0.82	0.52
GSK GSK	0.81	0.82	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CSLLY CSL	0.03%
GSK GSK	15.74%
GSK GSK	15.74%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
CSLLY CSL	N/A
GSK GSK	10.00%
GSK GSK	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	277.11 million	265.19 million	Optionable
CSLLY CSL	29,904	1.92 billion	N/A	Not Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable

AKBA, CSLLY, GSK, and GSK Headlines

Recent News About These Companies

Kahn Brothers Group Inc. Makes New $8.30 Million Investment in GSK PLC Sponsored ADR $GSK

August 28 at 6:25 AM | marketbeat.com

Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more

August 27 at 2:07 PM | statnews.comS

GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients

August 26 at 8:03 PM | finance.yahoo.com

GSK’s shingles shot cuts cardiovascular risk compared with Merck’s Zostavax

August 26 at 3:02 PM | msn.com

GSK-owned ViiV wins FDA label expansion for HIV drug Tivicay for newborns

August 26 at 8:58 AM | seekingalpha.com

GSK’s Shingles Vaccine Linked to Lower Risk of Heart Disease

August 26 at 8:58 AM | bloomberg.com

US FDA accepts for priority review GSK’s sBLA for Jemperli for dMMR/MSI-H locally advanced rectal cancer

August 25, 2026 | pharmabiz.comP

GSK shares drift despite drug approvals boost

August 25, 2026 | msn.com

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

August 24, 2026 | zacks.com

GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy

August 24, 2026 | reuters.com

Company mergers can cut costs without cutting prices for consumers, study finds

August 21, 2026 | phys.orgP

GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth

August 20, 2026 | proactiveinvestors.co.uk

A Look at GSK PLC (GSK) After 3.4% Gain -- GF Value $45.43 vs Price $52.88

August 19, 2026 | gurufocus.com

GSK India aims to double revenue to ₹8K cr by FY30: MD Bhushan Akshikar

August 16, 2026 | business-standard.comB

£6,000 in GSK shares 6 months ago is now worth…

August 16, 2026 | uk.finance.yahoo.com

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

August 13, 2026 | finance.yahoo.com

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

August 11, 2026 | cnbc.com

Parashmoni Deori joins GSK India as Corporate Communications Manager

August 11, 2026 | exchange4media.comE

GSK slides Monday, underperforms market

August 11, 2026 | marketwatch.com

GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages

August 6, 2026 | marketbeat.com

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

August 4, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, CSLLY, GSK, and GSK Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.88 -0.06 (-6.51%)

As of 08/28/2026 04:00 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CSL OTCMKTS:CSLLY

$30.92 -0.42 (-1.34%)

As of 08/28/2026 03:58 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$50.80 +0.53 (+1.05%)

As of 08/28/2026 03:58 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK NYSE:GSK

$50.80 +0.53 (+1.05%)

As of 08/28/2026 03:58 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, CSLLY, GSK, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, CSLLY, GSK, and GSK Earnings

Compare Dividends

Latest AKBA, CSLLY, GSK, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, CSLLY, GSK, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, CSLLY, GSK, and GSK Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

CSL OTCMKTS:CSLLY

GSK NYSE:GSK

GSK NYSE:GSK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, CSLLY, GSK, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, CSLLY, GSK, and GSK Earnings

Compare Dividends

Latest AKBA, CSLLY, GSK, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, CSLLY, GSK, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, CSLLY, GSK, and GSK Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

CSL OTCMKTS:CSLLY

GSK NYSE:GSK

GSK NYSE:GSK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools